Zhongguo linchuang yanjiu (May 2023)
Clinical value of serum C1q tumor necrosis factor related protein 12 in predicting type 2 diabetic nephropathy
Abstract
Objective To investigate the predictive role of serum C1q tumor necrosis factor related protein 12(CTRP12) level in patients with type 2 diabetes mellitus(T2DM) and diabetic nephropathy(DN). Methods Using a cross-sectional, single center study design, 60 patients with T2DM(T2DM group), 70 patients with T2DM and DN(T2DM+DN group), and 60 healthy subjects(control group) admitted to Haikou Peoples Hospital from January 2020 to December 2020 were selected. According to urinary albumin excretion rate(UAER), patients in T2DM+DN group were divided into microalbuminuria DN subgroup(38 cases) and macroalbuminuria DN subgroup(32 cases). The level of serum CTRP12 was measured by enzyme-linked immunosorbent assay. ROC curve was used to evaluate the diagnostic efficacy of serum CTRP12 in T2DM and DN. Results The level of serum CTRP12 in macroalbuminuria DN subgroup was(348.65±53.24)pg/mL, that in microalbuminuria DN subgroup was(472.61±68.59)pg/mL, that in T2DM group was(455.81±84.62)pg/mL, and that in control group was(568.61±105.35)pg/mL, there was significant difference between groups(P<0.01). The low level of serum CTRP12 was a risk factor for T2DM and DN(P<0.05). The area under the curve of serum CTRP12 level in the diagnosis of T2DM and DN was 0.844(95%CI: 0.801-0.906), the best predictive value of serum CTRP12 was 418.26 pg/mL, the sensitivity was 81.89%, and the specificity was 74.55%. Conclusion The level of serum CTRP12 decreased significantly in patients with T2DM and DN. The decrease of serum CTRP12 level may have some predictive value for T2DM patients with DN.
Keywords